Filana Therapeutics (MEX:FLNA) Tariff Resilience Score: 7/10 (As of Jul. 13, 2026)


MEX:FLNA Filana Therapeutics Inc MEX:FLNA
33 GF Score
Price MXN23.00
! 2 Warning Signs
View Full Analysis

What is Filana Therapeutics Tariff Resilience Score?

Filana Therapeutics MEX:FLNA 33 Tariff Resilience Score is 7 as of Jul. 13, 2026. GuruFocus rates MEX:FLNA with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 1,370 Biotechnology companies, Filana Therapeutics ranks better than 90.36% on this metric.

Filana Therapeutics has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

Filana Therapeutics has Cassava Sciences has limited exposure to tariffs due to its focus on domestic R&D and clinical trials. Its minimal reliance on international supply chains and strong IP position offer resilience against trade disruptions.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Filana Therapeutics might have Highly Resilient.

Filana Therapeutics  (MEX:FLNA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Filana Therapeutics Tariff Resilience Score Related Terms

MEX:FLNA vs BOLD, INKT, XLO: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Filana Therapeutics's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Filana Therapeutics Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Filana Therapeutics's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Filana Therapeutics's Tariff Resilience Score falls into.


MEX:FLNA
33GF Score
Filana Therapeutics Inc MEX:FLNA
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
Filana Therapeutics (MEX:FLNA) has a Tariff Resilience Score of 7 as of Jul. 13, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Filana Therapeutics ranks #132 out of 1370 companies in the Biotechnology industry, placing it in the top 9.6%.
Is Filana Therapeutics' Tariff Resilience Score too high?
Filana Therapeutics' current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. Filana Therapeutics' value of 7 is 75% above this industry median. Based on the distribution chart, Filana Therapeutics ranks #132 out of 1370 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Filana Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Filana Therapeutics' Tariff Resilience Score compare to BOLD and INKT?
According to the Biotechnology industry distribution chart, Filana Therapeutics ranks #132 out of 1370 companies for Tariff Resilience Score. This places Filana Therapeutics in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Filana Therapeutics' value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,370 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Filana Therapeutics's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Filana Therapeutics's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Filana Therapeutics stock overvalued right now?
Filana Therapeutics (MEX:FLNA) has a current Tariff Resilience Score of 7. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. Filana Therapeutics' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Filana Therapeutics (MEX:FLNA), the current Tariff Resilience Score is 7 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Filana Therapeutics Business Description

Other Exchanges FLNA:USAPX91:Germany
Address 6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
33GF Score

Get the complete analysis for MEX:FLNA

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN23.00
Price